Published in Int J Biochem Cell Biol on July 30, 2008
Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res (2011) 3.18
Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma. Stem Cells (2009) 1.26
Nuclear receptors Nur77 and Nurr1 modulate mesenchymal stromal cell migration. Stem Cells Dev (2011) 0.95
Increased migration of human mesenchymal stromal cells by autocrine motility factor (AMF) resulted in enhanced recruitment towards hepatocellular carcinoma. PLoS One (2014) 0.88
Analysis of chemotactic molecules in bone marrow-derived mesenchymal stem cells and the skin: Ccl27-Ccr10 axis as a basis for targeting to cutaneous tissues. Cytotherapy (2013) 0.85
NAP-2 Secreted by Human NK Cells Can Stimulate Mesenchymal Stem/Stromal Cell Recruitment. Stem Cell Reports (2016) 0.79
Bone formation in rabbit's leg muscle after autologous transplantation of bone marrow-derived mesenchymal stem cells expressing human bone morphogenic protein-2. Indian J Orthop (2014) 0.79
Study on chemotaxis and chemokinesis of bone marrow-derived mesenchymal stem cells in hydrogel-based 3D microfluidic devices. Biomater Res (2016) 0.76
Bone Marrow-Derived Mesenchymal Stromal Cells from Patients with Sickle Cell Disease Display Intact Functionality. Biol Blood Marrow Transplant (2017) 0.75
Chemotaxis-driven disease-site targeting of therapeutic adult stem cells in dystrophic epidermolysis bullosa. Stem Cell Res Ther (2016) 0.75
Identification of crucial genes in intracranial aneurysm based on weighted gene coexpression network analysis. Cancer Gene Ther (2015) 0.75
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia (2009) 4.91
Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med (2002) 4.54
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Chitosan: a versatile biopolymer for orthopaedic tissue-engineering. Biomaterials (2005) 2.60
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood (2011) 2.13
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol (2009) 2.13
Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol (2007) 2.09
Scaffold-based tissue engineering: rationale for computer-aided design and solid free-form fabrication systems. Trends Biotechnol (2004) 1.93
Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem (2007) 1.86
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol (2002) 1.75
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood (2011) 1.75
Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells. Blood (2007) 1.70
Role of interleukin 16 in multiple myeloma. J Natl Cancer Inst (2012) 1.62
Mechanical testing of fixation techniques for scaffold-based tissue-engineered grafts. J Biomed Mater Res B Appl Biomater (2007) 1.61
Cis- and trans-acting gene regulation is associated with osteoarthritis. Am J Hum Genet (2006) 1.55
Periosteal cells in bone tissue engineering. Tissue Eng (2003) 1.54
Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum (2010) 1.53
Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum (2008) 1.53
Treatment of posttraumatic and focal osteoarthritic cartilage defects of the knee with autologous polymer-based three-dimensional chondrocyte grafts: 2-year clinical results. Arthritis Res Ther (2007) 1.45
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone (2008) 1.44
Autoregulation of Th1-mediated inflammation by twist1. J Exp Med (2008) 1.43
BMP2 initiates chondrogenic lineage development of adult human mesenchymal stem cells in high-density culture. Differentiation (2003) 1.42
Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol (2013) 1.39
Specific lineage-priming of bone marrow mesenchymal stem cells provides the molecular framework for their plasticity. Stem Cells (2009) 1.37
Transcriptional profiles discriminate bone marrow-derived and synovium-derived mesenchymal stem cells. Arthritis Res Ther (2005) 1.37
Priming integrin alpha5 promotes human mesenchymal stromal cell osteoblast differentiation and osteogenesis. Proc Natl Acad Sci U S A (2009) 1.35
The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs (2008) 1.31
Angiogenesis in multiple myeloma. Eur J Cancer (2006) 1.31
Myeloma bone disease and proteasome inhibition therapies. Blood (2007) 1.29
Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study. Arthritis Res Ther (2008) 1.28
Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol (2006) 1.27
The human nose harbors a niche of olfactory ectomesenchymal stem cells displaying neurogenic and osteogenic properties. Stem Cells Dev (2010) 1.25
Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood (2006) 1.22
Chondrogenic differentiation potential of osteoarthritic chondrocytes and their possible use in matrix-associated autologous chondrocyte transplantation. Arthritis Res Ther (2009) 1.21
Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol (2006) 1.21
A microcarrier-based cultivation system for expansion of primary mesenchymal stem cells. Biotechnol Prog (2007) 1.19
Human platelet-rich plasma stimulates migration and chondrogenic differentiation of human subchondral progenitor cells. J Orthop Res (2011) 1.19
Formation of cartilage repair tissue in articular cartilage defects pretreated with microfracture and covered with cell-free polymer-based implants. J Orthop Res (2009) 1.19
Relative percentage and zonal distribution of mesenchymal progenitor cells in human osteoarthritic and normal cartilage. Arthritis Res Ther (2011) 1.19
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol (2013) 1.19
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica (2006) 1.16
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma (2010) 1.14
Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res (2003) 1.14
Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol (2008) 1.13
Regeneration of ovine articular cartilage defects by cell-free polymer-based implants. Biomaterials (2007) 1.12
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol (2007) 1.11
Treatment of fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol (2003) 1.11
CD44 is a determinant of inflammatory bone loss. J Exp Med (2005) 1.10
Treatment of focal degenerative cartilage defects with polymer-based autologous chondrocyte grafts: four-year clinical results. Arthritis Res Ther (2009) 1.10
Porcine mesenchymal stem cells. Induction of distinct mesenchymal cell lineages. Cell Tissue Res (2002) 1.10
Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol (2008) 1.10
Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol (2003) 1.09
Highly efficient magnetic stem cell labeling with citrate-coated superparamagnetic iron oxide nanoparticles for MRI tracking. Biomaterials (2012) 1.08
Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun (2005) 1.07
Quantitative determination of the diagnostic accuracy of the synovitis score and its components. Histopathology (2010) 1.07
Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life in patients with cancer of the oesophagus, the oesophago-gastric junction and the stomach. Eur J Cancer (2007) 1.07
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22. Eur J Cancer (2008) 1.07
Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients. Eur J Haematol (2009) 1.05
Detailed analysis of the variability of peptidylarginine deiminase type 4 in German patients with rheumatoid arthritis: a case-control study. Arthritis Res Ther (2006) 1.05
Stem cells for regenerative medicine: advances in the engineering of tissues and organs. Naturwissenschaften (2002) 1.04
Proteasome: an emerging target for cancer therapy. Anticancer Drugs (2005) 1.04
Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther (2006) 1.04
Human periosteum-derived progenitor cells express distinct chemokine receptors and migrate upon stimulation with CCL2, CCL25, CXCL8, CXCL12, and CXCL13. Eur J Cell Biol (2008) 1.04